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Abstract: In the past, patients with severe hemophilia have suffered a substantially reduced 
quality of life with frequent bleeding episodes, disabling arthropathy, and shorter life expectancy. 
In addition, methods of treatment and management have been costly and time-consuming, and 
have placed a considerable burden on patients’ physical and psychological well-being. With the 
advent of the on-demand therapy and prophylactic treatment paradigm, patients have been able 
to receive care with less interruption of daily activities. Treatments may be more challenging 
for hemophiliacs with inhibitors to replacement factor; however, recent advances in the use of 
bypassing agents and immune tolerance therapy have enabled them to aggressively manage 
their disease while maintaining their independence. This review focuses on the challenges of 
treating such a severe hemophiliac through examination of the lifetime experience of a young 
adult male with a severe form of congenital hemophilia A. At this stage of his life, the patient 
has minimal disabilities and is inhibitor-free through optimal care and strong family support. 
His aspiration to pursue a productive life has led him to a career in medicine. After receiving 
his medical degree, he pursued a specialty in the treatment of hemophilia. By assisting other 
hemophilia patients, he exemplifies both the rewards of persevering through episodes of bleed-
ing and other complications and the fact that disabilities can be minimized when managed 
meticulously and in a timely fashion to enable a productive and dignified life.
Keywords: hemophilia, quality of life, factor VIII inhibitors, hemophilia treatment center, 
early treatment, bypassing agent
Introduction
The management and care of patients with hemophilia have evolved greatly over the 
last 40 years. Historically, children with hemophilia have had a poor quality of life 
and have rarely survived past the first decade of life.1 Today, children and adults with 
hemophilia participate daily in school and work activities, and can expect a fairly normal 
life expectancy. These critical gains can largely be attributed to scientific advances in 
our understanding of hemophilia that have been translated into vast improvements in 
disease management and patient care.
This article highlights the case of a 27-year-old Asian male who was diagnosed 
as having severe hemophilia at the time of his birth. He initially received on-demand 
factor VIII (FVIII) infusion and a subsequent prophylactic regimen. The patient devel-
oped a factor inhibitor before adolescence, successfully underwent immune tolerance 
therapy (ITT) for his inhibitor, and has since remained inhibitor-free. The supplemen-
tation of a relatively routine treatment paradigm with strong familial involvement and 
prompt, diligent medical support for his bleeding episodes undoubtedly minimized any 
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potential disease-related complications, including disabling 
arthropathy, in this patient.
Patient history
The patient is one of 30% to 40% of congenital hemophilia 
cases without a familial history of hemophilia. His disease 
was induced by a spontaneous genetic mutation,2,3 and was 
diagnosed at birth when a forceps-assisted delivery resulted 
in prominent cranial bruising and a soft-tissue hematoma. His 
parents were actively involved in his care and were protective 
during infancy and childhood. The patient avoided contact 
sports during childhood, but still had severe hemarthroses in 
both ankles. Currently, he has minimal joint arthropathy, as 
measured by regularly scheduled imaging studies and clini-
cal evaluations. Although fairly active as a child, the patient 
struggled with weight gain from 10 to 16 years of age.
Prior to the age of 12, the patient developed inhibitors; 
however, the exact time and highest titer that developed dur-
ing this period is unknown due to the lack of medical records. 
Although the therapeutic (such as a cryoprecipitate) used 
in childhood was unknown, the patient received intensive, 
episodic treatment with infusions of FVIII concentrates 
from childhood and into early adulthood. His ankle bleeds 
were often not treated when he was a child, which may have 
contributed to his avoidance of human immunodeficiency 
virus (HIV) and/or hepatitis C virus (HCV) infection from 
plasma-derived products available at that time; he is currently 
negative for both HIV and HCV .
This patient has used bypassing agents to treat bleeding 
episodes in target joints (bilateral ankles and left elbow) and 
hematomas, including two bleeds in his iliopsoas muscle, the 
first on his right side at age 15 and the second on his left side 
at age 23. He experienced approximately one bleed per target 
joint every 2 to 3 months when he was younger and, prior to 
the age of 18, relied primarily on physical therapy to manage 
bleeding events. Later, plasma-derived activated prothrombin 
complex concentrate (pd-aPCC, FEIBA NF [Anti-Inhibitor 
Coagulant Complex; Baxter Healthcare Corporation, Westlake 
Village, CA]) was used on demand for treatment of bleeding 
events. More recently, he has begun self-administration of 
prophylactic therapy using bypassing agents three times a 
week and on the mornings of strenuous days. Because the 
patient lacks a central venous access device, he performs 
venipuncture on himself at an average rate of three to four 
times a week. After being treated for bleeds at a hemophilia 
treatment center (HTC) as a young child, the patient moved 
with his family to Charlotte, North Carolina, where he received 
treatment for bleeds by a local hematologist who was not part 
of an HTC network. While the patient matriculated as an 
undergraduate at the University of South Carolina in Columbia, 
he returned to receive treatment at the HTC where he had been 
treated as a child. The patient currently receives treatment for 
bleeds at an HTC in Tampa, Florida, and maintains a healthy 
lifestyle as a medical doctor.
Epidemiology
Hemophilia A is an X-linked genetic bleeding disorder 
caused by a deficiency in or absence of clotting FVIII. In 
North America and Europe, the incidence of hemophilia 
A is approximately 1 in 5000 male births.4 The prevalence 
is 20.6 cases per 100,000 males, of which 60% have severe 
disease. In approximately 40% of cases of severe hemophilia, 
the mutation involves a large inversion that interferes with the 
FVIII gene, while the remaining cases typically involve point 
mutations, deletions, and insertions.5–7 A diagnosis of congeni-
tal hemophilia in its severe form (less than 1% of circulating 
FVIII) is most often made during or shortly after birth, par-
ticularly during assisted deliveries and circumcisions.8
Inhibitors
Inhibitors developing in patients with hemophilia A bind to 
and inactivate FVIII,9 which is a result of repeated patient 
exposure to FVIII. Inhibitors are classified as “high titer” 
when the immune response is robust (ie, a titer is greater 
than 5 Bethesda units [BU]). Several prospective studies have 
determined that 20% to 30% (in the child population, up to 
50%)10 of patients with severe hemophilia A will develop 
inhibitors to FVIII early in life, even with relatively little 
exposure.11,12 Several studies have demonstrated a correla-
tion of the presence of inhibitors with greater morbidity and 
a poor quality of life.13–15 Patients with severe hemophilia are 
at the greatest risk for developing inhibitors, which generally 
appear within the first 10 to 20 days of exposure to FVIII 
concentrate.11,12,16 Once patients with hemophilia develop 
inhibitors, treatment becomes more challenging and preven-
tion of orthopedic complications more difficult.17 Inhibitor 
development has a considerable impact on patient morbidity 
and up-front treatment costs.18 However, it has been demon-
strated that improvements in both clinical outcomes19,20 and 
quality of life (days gained at work and school, fewer days 
of hospitalization, fewer hospitalizations, and a reduced need 
for surgery) result in ultimate economic benefit.21,22
Arthropathy
Beyond infancy, hemarthroses account for the majority 
of bleeds in hemophilic patients (70%–80%).23,24 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
18
Saba and TranJournal of Blood Medicine 2012:3
Consequently, arthropathy is the most common and 
debilitating long-term sequela in patients with hemophilia, 
typically occurring during the second or third decade of 
life.25,26 The chronic arthropathy resulting from uncontrolled 
bleeding has a debilitating effect on patients with hemophilia, 
especially young patients whose joints are under continual 
development. While many hemophilic patients in their twen-
ties and thirties have severe arthropathy and disability, the 
patient discussed in this review has largely avoided this fate 
through prompt management of bleeding episodes. Early 
recognition and treatment of hemarthroses – made possible by 
the vigilance of the patient and his parents and the subsequent 
intervention of knowledgeable, experienced healthcare pro-
viders – have likely contributed to this outcome, by reducing 
the amount of and duration of bleeding into affected joints.27 
In addition, given the association between repeated episodes 
of bleeding and joint damage,28 reduction of the number of 
bleeding episodes through such measures as prophylaxis 
and activity modification likely played a role in this patient’s 
avoidance of severe, disabling arthropathy.
Treatment
In 1965, FVIII concentrate was first manufactured using a 
cryoprecipitation procedure that was easily copied by blood 
banks to be utilized for the routine treatment of joint and 
muscle bleeds.1,29 Although this procedure provided great 
clinical benefits to patients with hemophilia, it also brought 
about an increased risk of blood-borne viral infections. Viral 
transmission of HIV and HCV occurred in the hemophilia 
community via infected human plasma products.30 In 2004, 
it was estimated that at least one third of hemophilic patients 
were infected with HIV , and 80% with HCV . This tragedy 
for the hemophilia community led to the implementation of 
screening and viral inactivation processes through the use 
of heat treatment or affinity chromatography.31 Although 
plasma-derived products are safer now than ever before, 
concerns remain about infectious agents that may be resistant 
to existing methods for viral, chemical, or even physical 
inactivation,32,33 such as non-lipid-enveloped viruses like 
the parvoviruses or the prion that causes variant Creutzfeldt-
Jakob disease, which has been identified in blood transfusion 
recipients in the United Kingdom.34 Further, although there 
have been no reported cases of HIV or HCV transmission via 
clotting factor since 1986 and 1997, respectively,35 a recent 
case of HIV transmission from the transfusion of fresh frozen 
plasma in the USA in 200836 emphasizes the fact that the risk 
for transmission of enveloped viruses from human-derived 
blood products is not zero. Though negligible, this potential 
for transmission of infectious agents from plasma-derived 
products has driven the preferential use and ongoing develop-
ment of recombinant products for hemophilia treatment.
Dramatic improvements in patient outcomes have been 
seen in hemophilic patients without inhibitors who have 
undergone the combined use of on-demand plasma-derived 
replacement FVIII and prophylactic therapy beginning at 1 
to 2 years of age. Patients with severe hemophilia had a life 
expectancy of 11 years in the 1960s, compared with a life 
expectancy of 50 years and older in the 1980s.37,38 Data 
collected from 1993 to 1995 show that the age-adjusted 
mortality rates for hemophilic patients were four times those 
of the general US male population.39 Modern treatment aims 
to reduce the mortality rate and improve the quality of life of 
hemophilic patients by preventing bleeds through aggressive 
on-demand and prophylactic treatment regimens, along with 
lifestyle modifications.40,41
Hemophilic patients with high-titer inhibitors have 
more-limited treatment options than do patients without 
inhibitors. The aims of treating hemophilic patients with 
inhibitors are to stop acute bleeding episodes and maintain 
hemostasis (both typically through the use of bypassing 
agents), and to suppress the inhibitor by ITT. Currently, two 
bypassing agents are available for treating hemophilia A 
patients with inhibitors: recombinant factor VIIa (rFVIIa; 
NovoSeven® RT Coagulation Factor VIIa [Recombinant] 
Room Temperature Stable; Novo Nordisk A/S, Bagsvaerd, 
Denmark)42 pd-aPCC.43 These agents bypass the FVIII-depen-
dent step in the coagulation cascade and promote hemostasis 
by enhancing thrombin generation. Recombinant factor VIIa 
is also recommended to maintain hemostasis in hemophilic 
patients with high-titer inhibitors prior to the initiation of 
ITT, in order to allow inhibitor titers to decrease to below 10 
BU and thus increase the likelihood for treatment success.44 
This regimen is used to avoid possible anamnesis induced 
by blood products that contain FVIII.
ITT consists of administering repeated high doses of 
FVIII to a patient over a period of weeks to months to 
tolerize his immune system, thereby eliminating inhibitors. 
This procedure later allows replacement FVIII to continue 
to be used effectively for treatment.44 In the International 
Immune Tolerance Registry and the North American Immune 
Tolerance Registry, ITT was successful in 82% of patients 
with inhibitor peak titers that were less than 50 BU.45 An 
inhibitor titer of less than 10 BU at the start of ITT was a 
strong indicator of its success. However, in the   International 
Immune Tolerance Study, a   randomized, controlled study 
comparing high-dose (200 IU/kg/d)   versus low-dose 
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(50 IU/kg three times per week) regimens in “good-risk” 
patients with immediate pre-ITT inhibitor titers less than 
10 BU and historical peak titers greater than 10 BU, ITT 
was successful in only 69.7% of patients, with no differences 
in success rates in the high-dose versus low-dose treatment 
arms.45 The times to achieve a negative titer and the frequency 
of bleeding episodes were significantly reduced in the high-
dose group, but these findings did not ultimately influence 
the outcomes. ITT was successfully used in our patient as 
his last treatment, and he has remained inhibitor-free in the 
interim.
Prophylaxis and episodic treatment 
of bleeding episodes
Patients with severe hemophilia can experience spontaneous 
or trauma-related bleeding into joints, leading to painful and 
debilitating arthropathy. It is generally accepted today that 
prophylactic treatment may prevent hemarthroses and mus-
culoskeletal complications in patients with hemophilia who 
have not developed inhibitors.24 Several cohort studies and a 
more recent prospective randomized study demonstrated that 
primary prophylaxis may delay or prevent the development 
of hemophilic arthropathy.20,46,47 The efficacy of secondary 
prophylaxis in an adult patient with hemophilia has also been 
reported.48 In patients with inhibitors, prophylactic versus 
on-demand administration of bypassing agents has likewise 
been shown to have several important clinical benefits, 
including a reduced number of hemarthroses and overall 
bleeding episodes.49–51 Prophylaxis is expensive, as is ITT, and 
the need for frequent venipuncture or an indwelling central 
venous access device makes prophylactic treatment difficult 
for caregivers and patients, especially children.52
An alternative to prophylaxis is early and aggressive 
episodic treatment. Recent studies have provided evidence 
suggesting that prophylactic treatment has important clinical 
advantages over episodic on-demand treatment, including 
fewer bleeding episodes, better orthopedic function, and 
improved overall quality of life.20,46,47 Few episodic studies, 
however, have adequately controlled for time to treatment, 
which, when performed within 1 to 2 hours, is associated 
with fewer bleeding episodes, more rapid bleed control, and 
a smaller quantity of clotting agent required for control.19
The optimal regimen for the dosing and the frequency of 
factor concentrate infusions used for prophylaxis in children 
is unknown.13 The current protocol in the USA is 25 IU/kg 
to 40 IU/kg of FVIII three times a week for hemophilia 
A.24 It has been demonstrated that long-term outcomes 
are best achieved when prophylactic treatment is started 
before the age of 3 years.20,46,47 Fewer adults and adolescents 
than children receive prophylactic treatment, and currently 
there is no consensus as to when, or whether, prophylactic 
treatment could be discontinued in these patients.53,54 The 
risk of bleeding is lower in adulthood than in childhood and 
adolescence, as a result of joint maturity and a reduction in the 
degree of physical activity. Elderly patients with hemophilia 
typically also have a low incidence of hemarthrosis because 
of severe arthropathy.15
Patient’s experience
Despite beginning prophylactic therapy relatively late in 
life as an adult and his early development of inhibitors, 
the functional ability of our patient, as presented in this 
review, is remarkable. He completed medical school and 
a residency, both challenging even for the most physically 
fit of individuals. As an adult with the experience of many 
years of treating his condition, the patient knows how 
and when to avoid overexerting himself; for example, by 
utilizing a wheelchair when necessary. He is also proficient 
at determining when a joint “feels” as though it may need 
to be carefully managed with early treatment; in this case, 
when there is a reduction in range of motion.
Primary care and hemophilia 
treatment centers
The patient and his family have maintained a long-lasting, 
professional relationship with their primary care physician. 
This type of relationship is critical for long-term care in 
hemophilia, especially with respect to prophylaxis. The 
adolescent-to-adult transition is a particularly difficult time, 
when many patients are suddenly responsible for their own 
care.40 It is at this time that many hemophilic patients who 
were previously on prophylactic therapy may experience 
a lapse in their treatment, with worsening arthropathy as 
a result.54,55 A recent retrospective study predicted that an 
increase of only one primary care physician per 10,000-per-
son population was associated with an average mortality 
reduction of 49 per 100,000 people per year (or 5.3%).56 
Studies carried out by the Centers for Disease Control and 
Prevention also showed that hemophilic patients treated at 
HTCs have a 40% lower mortality rate than patients treated 
in local hospitals, even though the former population tends 
to have more severe disease.39
Additional patient experiences
In addition to receiving proper medical treatment to prevent 
or treat bleeds, patients with hemophilia should be made 
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more aware of the need to minimize trauma, of psychosocial 
issues, and of the use of nonpharmacologic, alternative treat-
ment and disease-management options. The parents of this 
patient took great precautions early on to minimize the risk 
of bleeds in an environment that was not overprotective. For 
example, as an infant, he slept in a corner of the room with 
many blankets; padding was attached to furniture to guard 
against impacts; and it was stressed to friends and family 
members that he should be treated with extra care. Later, he 
avoided contact sports, which carry a high risk of trauma. 
However, other sports such as swimming or golf are recom-
mended by the National Hemophilia Foundation24 because 
they improve overall fitness, help to build muscle strength, 
and ultimately reduce the risk of joint bleeds.
The incidence of obesity in the hemophilic population is 
twice that of the general population, often a result of patient 
inactivity and parental overprotection.41,57,58 Excess body 
weight weakens already unstable joints, increasing both the 
number of hemarthroses and arthropic progression.59 Excess 
body weight also increases the quantity of clotting factor and 
the time it takes to administer replacement clotting factor. 
After reaching a maximum weight of 77 kg, this patient 
succeeded in reducing his weight to 54 kg during his junior 
and senior years in high school. Today, he is even more 
physically active than when he was an adolescent; he swims 
episodically and works out by lifting weights and utilizing 
an elliptical machine three times a week.
Nonpharmacologic approaches complement drug-based 
treatment, helping to minimize the risk of uncontrolled 
bleeding and its sequelae. Because the availability of clot-
ting factor concentrates is limited by cost in many healthcare 
systems, alternative management methods have been tried to 
help reduce the amount of drugs needed.24 Commonly used 
nonpharmacologic approaches include hydrotherapy and 
rest, ice, compression, and elevation  (RICE). Joint rest can 
be achieved through the use of splints, casts, a wheelchair, 
or crutches. For example, as a hospital resident, this patient 
made liberal use of a wheelchair for the purpose of resting 
his joints when on-call during strenuous periods.
Surgical and other invasive procedures historically 
have proved to be extremely difficult or impossible with 
hemophilic patients, especially those with inhibitors. 
Today, in addition to pharmacologic options for managing 
these patients, adjunctive approaches can be employed. 
For example, this patient underwent tooth extraction as an 
adolescent, and his parents applied tea bags to the affected 
area, significantly reducing the amount of bleeding from 
the procedure. Tea leaves contain tannic acid, which causes 
constriction of blood vessels; hence, moistened tea bags may 
provide a simple, localized hemostatic effect.60
Discussion
The case of the patient discussed in this review is a prime 
example of successful hemophilia management with early and 
aggressive on-demand therapy in addition to diligent parental 
involvement in bleed-preventive measures. This case is also 
illustrative of what has been achieved in the realm of diag-
nosis and treatment within a generation, and of what remains 
to be achieved to further minimize the morbidity resulting 
from severe hemophilia. Treatment for severe hemophilia has 
progressed swiftly, even within the lifetime of this patient, 
and it is promising to consider the long-term prognosis of 
hemophilic infants today, especially in light of the advances 
being made in prophylaxis and home infusion.20,53–55,61 This 
patient began prophylactic treatment only as an adult, having 
been treated early, on demand, as a child and an adolescent. 
As a consequence, over time, his joint morbidity has been 
kept to a minimum, with few sequelae from acute bleeding. 
His current degree of arthropathy, as evidenced by regular 
radiographic and clinical surveillance, is minimal, as is the 
impact of any arthropathy on his quality of life. He is able to 
meet the physical demands of his work without difficulty and 
maintains an active low-impact exercise regimen.
Bypassing agents are the treatment of choice in patients 
who have developed inhibitors from factor infusion, and 
have been used successfully for the prophylactic treatment 
of bleeds. This patient has been successfully treated using 
these agents in adulthood, and continues to use them as 
needed. Bypassing agents have greatly contributed to the 
prevention of arthropathy, and have provided this patient with 
the opportunity to maintain an independent and demanding 
lifestyle. His case highlights the importance of aggressive 
treatment from infancy, whether with prophylaxis or on 
demand, and of the absolute necessity for hypervigilant 
parental involvement in the home and school environment. 
Hemophilia requires the interaction of the whole healthcare 
team for optimal care of the patient. The ultimate goals for 
hemophilic patients and their healthcare providers are the 
prevention of joint bleeds, optimal function, and a superior 
quality of life.
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